We now carry OsPhos and Tildren for treatment of navicular disease.
What is OsPhos and Tildren?
OsPhos and Tildren are both injectable bisphosphonate solutions for the control of clinical signs associated with navicular syndrome in horses four years and older. OsPhos and Tildren both inhibits bone resorption (disappearance) by inhibiting cells called osteoclasts. Osteoclasts grab onto calcium crystals which comprise bone and dissolve them. By stopping osteoclast activity, OsPhos and Tildren slow bone degradation.
Does they work?
Clinical trials conducted by Dechra in order to comply with FDA testing requirements found that 75% of horses treated with OsPhos showed a significant reduction in lameness by 56-days post injection and 67% of horses treated with Tildren improved.
Are there side effects?
Minimal One in 10 horses showed signs of abdominal discomfort (pawing, fidgeting, cramping) about 2 hours post-injection, but got over it after a 15 minute walk. Some were given a dose of banamine but none had serious or lasting reactions.
How is it given?
OsPhos is administered as three 5 cc intramuscular injections given in three locations on the body all at once. Tildren is given by a veterinarian through an IV catheter slowly over 90 minutes. They can be given every 3 to 6 months depending on the severity of the lameness, but ultimately should only be repeated as needed when signs of lameness recur. Some horses may only need it once, while others many need it two or three times per year.
How do they compare?
In many ways, OsPhos holds its own against Tildren:
◾OsPhos costs $375 per treatment while Tildren is $1,200. OsPhos was only recently FDA approved this fall. Tildren was FDA approved 1 year ago in the USA but has been used for years in Europe with great success.
◾OsPhos can be given intramuscularly while Tildren has to be given intravenously. In addition, Tildren has to be given slowly IV over 90 minutes.
◾OsPhos shows similar results to Tildren in terms of reduction in lameness and in time of onset. Tildren definitely exerts a long term effect, with many owners reporting that it reaches full performance 3 months following administration and continues to work for years thereafter. Because OsPhos is so new, we will have to wait and see how it measures up to Tildren over the long haul.
We are excited to see the promising results of OsPhos. We just started using OsPhos in December 2014 and have treated approximately 10 horses so far.